In Part B, a lower single dose of HER3-DXd (5.6 mg/kg) was evaluated in 20 patients with untreated early-stage HR+/HER2- breast cancer and 17 patients with triple-negative breast cancer (TNBC)8. This evidence concerns the gene ERBB3 and breast cancer.